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CLINICAL TRIAL ENROLLMENT IN A MULTIDISCIPLINARY PROSTATE CANCER
CLINIC

Publication No. ______________

Delora Alyce Domain, MS, BS
Supervisory Professor: Thomas Buchholz, MD
Purpose: Clinical oncology trials are hampered by low accrual rates. Less than 5% of adult
cancer patients are treated on a clinical trial. We aimed to evaluate clinical trial enrollment
in our Multidisciplinary Prostate Cancer Clinic and to assess if a clinical trial initiative,
introduced in 2006, increased our trial enrollment.
Methods: Prostate cancer patients with non-metastatic disease who were seen in the clinic
from 2004 to 2008 were included in the analysis. Men were categorized by whether they
were seen before or after the clinical trial enrollment initiative started in 2006. The initiative
included posting trial details in the clinic, educating patients about appropriate clinical trial
options during the treatment recommendation discussion, and providing patients with
documentation of trials offered to them. Univariate and multivariate (MVA) logistic
regression analysis evaluated the impact of patient characteristics and the clinical trial
initiative on clinical trial enrollment.
Results: The majority of the 1,370 men were white (83%), and lived within the surrounding
counties or state (69.4%). Median age was 64.2 years. Seventy-three point five percent
enrolled in at least one trial and 28.5% enrolled in more than one trial. Sixty-seven percent
enrolled in laboratory studies, 18% quality of life studies, 13% novel studies, and 3.7%
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procedural studies. On MVA, men seen in later years (p < 0.0001) were more likely to
enroll in trials. The proportion of men enrolling increased from 38.9% to 84.3% (p<0.0001)
after the clinical trial initiative. On MVA, older men (p < 0.0001) were less likely to enroll
in clinical trials. There was a trend toward men in the high-risk group being more likely to
participate in clinical trials (p = 0.056). There was a second trend for men of Hispanic,
Asian, Native American and Indian decent being less likely to participate in clinical trials (p
= 0.054).
Conclusion: Clinical trial enrollment in the multidisciplinary clinic increased after
introduction of a clinical trial initiative. Older men were less likely to enroll in trials. We
speculate we achieved high enrollment rates because 1) specific trials are discussed at time
of treatment recommendations, 2) we provide a letter documenting offered trials and 3) we
introduce patients to the research team at the same clinic visit if they are interested in trial
participation.
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Introduction
Prostate Cancer
Prostate Cancer (PCa) is a tumor of the prostate gland that occurs when normal
glandular cells mutate into malignant cancer cells whose growth, function, and proliferation
is no longer under the body’s regulatory control. The majority of prostate cancers are
adenocarcinomas, an epithelial cancer that originates within glands and/or glandular tissue
(Crawford, 2009). However, a small percentage can develop from aberrant squamous cells,
signet ring, transitional cells or even neuro-endocrine stem cells all normally found in the
prostate (Bracarda, et al., 2005). PCa is more likely to be a quiescent localized disease with
a protracted course but it can also manifest as a rapidly progressing tumor with high
metastatic potential (Crawford, 2009). PCa tends to be a highly heterogeneous disease.
This is partly due to the biology and morphology of the prostate gland.
The prostate gland itself is an integral part of the male genitourinary system, located
in the pelvic cavity, nestled between the urinary bladder and the rectum. It is responsible for
the production and storage of seminal fluid and is typically classified into 3 different zones:
central, transition and the peripheral zone. Although the tumor may originate in one specific
zone of the prostate, the majority of these tumors have multiple separate copies scattered
throughout all three zones of the prostrate (Crawford, 2009). Because of this, prostate
cancers are considered by convention to be multifocal/multi-centric tumors. Furthermore,
these multicentric lesions can and often do have differing glandular patterns and degrees of
tumor cell differentiation (Bracarda et al., 2005). Localized prostate tumors tend to spread
first to the seminal vesicles, urinary bladder and the surrounding tissues (Bracarda et al.,

1	
  

2005). Prostate tumors metastasize primarily to the bone, via the lymphatic system or direct
hematogenous (Bracarda et al., 2005).

Prevalence and Incidence
One in 6 men over the age of 50 will be diagnosed with PCa in their lifetime; of
these, 1 in 33 will die of the disease (Weissbach et al., 2009). Despite this seemingly
moderate death rate, studies show that PCa is second only to lung caner in cancer-related
mortality in men (Jemal et al., 2010). The American Cancer Society reported 217,730
newly diagnosed cases of PCa and 32,050 deaths in the US in 2010 alone (Rosenberg et al.,
2010; Jemal et al., 2010). The incidence of PCa has been on the rise since 1975 starting at
195 cases per 100,000 and spiking in 1992 to nearly 250 per 100,000 (Jemal et al., 2010).
This increase is mostly due to the advent of prostate-specific antigen (PSA) screening,
which was implemented in the late 1980s (Bracarda et al., 2005). Its widespread use leveled
off by the early 2000s, coinciding with the leveling off PCa incidence rates (Bracarda et al.,
2005). As of 2010, the US incidence of PCa was 155.5 cases per 100,000 (Jemal et al.,
2010). Screening and early detection have driven the mortality rates down. Currently, the
5-year survival rate for PCa approaches 100%, while the 10-year survival rate is 93%
(Rosenberg et al., 2010). PCa is a significant problem in the population at large. One way
to combat the problem is to learn more about the disease through education and research.

Screening and Diagnosis
Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells of
the prostate gland, and is mainly concentrated within the prostate gland (Greene et al, 2009).
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Serum PSA level is very low in an individual with normal prostate function, however
aberrant changes in the functionality and integrity of the prostate often gives rise to leakage
and elevated levels of PSA in the blood. Because of positive correlation between serum
PSA level and prostate abnormalities, serum PSA screening has been implemented as a
diagnostic and/or prognostic biomarker for prostate cancer. PSA screening guidelines vary
across different medical organizations. As of 2009, the age at which the American
Urological Association (AUA) recommends individuals obtain a baseline PSA has been
lowered from 50 years to 40 years for those at an average risk (non-African-American, no
family history) of prostate cancer development (Greene et al., 2009). Thereafter, individuals
are recommended to return for regularly scheduled PSA tests (Greene et al, 2009).
PSA, while being specific to the prostate gland, is not necessarily sensitive only to
PCa (Bracarda et al., 2005). Because elevated serum PSA is also highly characteristic of
non-cancerous prostate abnormalities (ex. prostatitis, benign prostate hyperplasia, etc.), a
digital rectal examine (DRE) is recommended in conjunction with a screening PSA test
(Bracarda et al., 2005). In the presence of an abnormal DRE and/or an elevated PSA, a
positive prostate biopsy is required for a differential diagnosis (Greene et al., 2009). A
review of all possible contributing factors such as PSA density and velocity, prostate size,
patient age and ethnicity, co-morbidities and previous prostate biopsy is also recommended
(Horwich, et al., 2010).

Risk Group
The inherent heterogeneity of prostate tumors necessitates an unique scoring system.
In addition to the standard TNM (Tumor, Node, Metastasis) staging for solid tumors,
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prostate cancers are subjected to the disease-specific Gleason score. The Gleason scoring
system is based specifically on the glandular pattern of the tumor and the degree of
differentiation of the tumor cells themselves (Bracarda et al., 2005). Tumors are stratified
into five different grades (1-5), with grade 5 having the worse prognosis (Bracarda et al.,
2005). The two most prominent grades of disease are added together to give a single
Gleason score which would then be used as a prognostic indicator. Unfortunately, Gleason
scores are only useful in scoring adenocarcinomas of the prostate. This tends not to be an
immediate concern since approximately 95% of prostate cancers are adenocarcinomas
(Bracarda et al., 2005).
Based on PSA level, Gleason score, and T-stage clinically localized tumors are
further categorized into prognostic recurrence risk groupings (Horwich et al., 2010). [See
Table 1 for the NCCN (National Comprehensive Cancer Network) risk group criteria.] Risk
group predicts the likely treatment outcome and guides the physician in making the
appropriate treatment recommendations. Risk group is also a key factor in the majority of
interventional clinical trials inclusion/exclusion criteria. Clinicians/Investigators also
consider patient age and life expectancy, co-morbidities and general health status (Horwich
et al., 2010).
Table 1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer risk group criteria,
Version 1. 2010.
Very Low
Intermediate
Very High
Low Risk
High Risk
Metastatic
Risk
Risk
Risk
T1a
T1 – T2a
T2b - T2c or
T3a or
(locally
(locally
Gleason ≤6
Gleason 2-6
Gleason 7 or
Gleason 8 –
Advanced
advanced
PSA <10
PSA 10-20
10
disease)
disease)
PSA <10
ng/mL
ng/mL
Or PSA >20
T3b – T4
Any T, N1
ng/mL
ng/mL
Any T, Any
< 3 + biopsy
N, M1
cores w/
≤50% cancer
PSA density
<0.15 ng/mL
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Treatment Options and Side Effects
Active surveillance consists of identification of prostate cancer patients with low or
very low risk disease who are then put on a periodic disease monitoring/re-staging schedule
until such time as a PSA test, DRE or other clinical indicator of progression crosses the risk
threshold, indicating the need for active treatment (Large et al., 2009). The main drawback
associated with the active surveillance approach is increased patient anxiety caused by the
psychosocial burden of living with an untreated cancer that may or may not have the
potential to progress and become life threatening (Andrew et al., 2010).
Radical prostatectomy (RP) is the surgical removal of the prostate gland (Andrew et
al., 2010). Along with the normal post-operative complications (i.e. pain, bleeding) RP
carries with it the threat of stress or total urinary incontinence, and erectile dysfunction
(possibly long-term) (Andrew et al., 2010).
Brachytherapy is the insertion of radioactive isotopes seeds into the prostate gland,
which would deliver a steady dose of therapeutic radiation to the tumor site and surrounding
tissues over time. Brachytherapy can be done with either temporary implants or permanent
ones (Horwich et al., 2010). The risk group generally determines whether the patient will
receive temporary or permanent implants. External beam radiotherapy is radiation therapy
that originates from a source outside the body. External beam radiotherapy uses a rotating
machine (gantry) to aim the radiation at the site of the patient’s cancer, in this case, the
prostate gland. Radiation treatment(s), whether it is external beam therapy or internal seed
implants, all carry the similar side effect profile: bladder, urethra or rectal irritation, frequent
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urination, burning urination and stronger urges to urinate, rectal soreness or bleeding, and
frequent bowel movements (Andrew et al., 2010).
Hormone therapy in the context of prostate cancer treatment consists of Androgen
Deprivation Therapy (ADT). ADT is generally a drug given to patients that reduces the
production and/or effects of androgenic hormones (i.e. testosterone) by preventing the
cancer cells from interacting with testosterone. This results in tumor shrinkage because
many prostate cancers require testosterone for growth and proliferation. LHRH (luteinizing
hormone-releasing hormone) agonists are drugs that work indirectly by inducing the
pituitary gland to release LHRH which cause the testicles to halt the production of
testosterone. Orchiectomy is the surgical removal of the testicles, which in turn guarantees a
substantial and permanent halt to testosterone production. The timing for giving hormone
therapy may vary (adjuvant, neo-adjuvant, post-relapse, post-metastasis) (Horwich et al.,
2010). All hormone therapies cause the same general side effects: impotence, weakness and
loss of muscle mass, osteoporosis, shrunken testicles (absent testicles in the case of
orchiectomy), and depression, low self-esteem, loss of aggressiveness/alertness, weight
gain/obesity and diabetes (Andrew et al., 2010). In recent years, there is some indication
that hormone therapy in men with prostate cancer can increase the risk of cardiovascular
disease and cardiovascular events (i.e. myocardial infarction) (Schwandt et al., 2009)
Two emerging therapy options for PCa that have been in the spotlight in recent years
are cryotherapy and HIFU. Both are focal therapies and still under interventional
investigation. Focal therapy is loosely defined as any form of incomplete prostate ablation
therapy (i.e. hemi-ablation, three quarter’s ablation) (Eggener et al., 2010). The overall
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Table 2: NCCN Practice Guidelines in Oncology, PCa Initial Treatment Recommendations, version
1. 2010.
Life
Initial Therapy
Adjuvant Therapy
Expectancy
Recommendation
Recommendations
Note: The NCCN believes that the best management for any cancer patient is in a clinical trial. Therefore,
participation in clinical trials is highly encouraged.
AS
PSA every 6 months
Very Low Risk
< 20yrs
DRE every 12 months
AS
<10
PSA every 6 months
DRE every 12 months
AS
PSA every 6 months
DRE every 12 months
Low Risk
Biopsy every 12 months
≥10
RT
Observation or RT
RP ± PLND
If + lymph nodes:
Observation or ADT
AS
PSA every 6 months
DRE every 12 months
RT ± short term ADT
<10 yrs
±Brachytherapy
Observe or RT
RP ± PLND
If + lymph nodes:
Intermediate Risk
Observe or ADT
Risk Group

RP ± PLND
≥10yrs

Observation or RT
If + lymph nodes:
Observation or ADT

RT
± short term ADT
± Brachytherapy
RT + long term ADT

High Risk

RP + PLND

Observation or RT
If + Lymph nodes:
Observation or ADT

RT + long term ADT
Very High Risk / Locally
Advanced

Metastatic
Any T, N1

RP + PLND

Observe or RT
If + Lymph nodes:
Observation or ADT

ADT
ADT
Or
RT + short term ADT

Metastatic
ADT
Any T, Any N, M1
AS = Active surveillance, ADT = Androgen deprivation therapy, DRE = Digital rectal exam, RT = Radiation
therapy, RP = Radical prostatectomy, PLND = Pelvic lymph node dissection.
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objectives of focal therapy are to a) selectively ablate tumor cells/tissue, b) preserve organ
function, and c) minimize treatment morbidity (Karavitakis et al., 2010).
Cryotherapy, more colorfully known as “the male lumpectomy”, is the localized
destruction of tissue using alternating cycles of extreme freezing and thawing (Lindner et al.,
2010, Lecornet et al., 2010). Cryotherapy is already known to have many advantages. It is
a one-time (often outpatient) treatment, which can be repeated as both a focal and a whole
gland treatment if necessary (Singh et al., 2010). However, it does carry with it the
worrisome risk of erectile dysfunction (Singh et al., 2010). Other known side effects of the
treatment are urethral fistula, urethral sloughing and incontinence, although the rates of
these effects are relatively low (Singh et al., 2010).
HIFU (High intensity focused ultrasound) therapy is the use of a tightly focused
ultrasound frequency (between 0.8 and 3.5 MHz) to generate high energy density which
when aimed at a specific point in the prostate gland causes heating, protein denaturation,
coagulative necrosis and ultimately tissue death/damage (Lecornet et al., 2010; Eggener et
al., 2010). Its use is associated with varying rates of the following side effects: urethral
strictures, urethro-rectal fistulas, urinary incontinence and impotence (Eggener et al., 2010).
Further observations and interventional studies of focal therapies need to be completed to
report on the full potential and/or limitations of both HIFU and cryotherapy. However, low
accrual rates on clinical trials have slowed efforts to refine these emerging therapies.
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Risk Factors and Etiology
To date, no direct cause of PCa has been clearly identified. Studies have suggested a
plethora of possible contributing factors (previous diagnosis of benign prostatic hyperplasia,
history of vasectomy, level of sexual activity, weight and diet, smoking, deficiency in
vitamin E or D, alcohol consumption etc.) but none of these have stood firm against rigorous
scientific investigation (Bracarda et al., 2005). However, there is consistent, corroborative
evidence to support several recognized risk factors that contribute to the development of
PCa: age, race, a positive family history, and a hereditary pre-disposition.
Studies and statistics show that the risk of prostate cancer increases with increasing
age. According to statistical analysis run on cancer-free US males from 2004 to 2006, from
birth to age 39, the probability of being diagnosed with PCa is only 1 in 9,422 (Jemal et al,
2010). For ages 40 to 50, the probability increases to 1 in 41, for ages 60 to 69 the
probability is 1 in 16, and for males 70 or older the probability of developing prostate cancer
peaks at 1 in 8 (Jemal et al, 2010). Additionally, the American Cancer Society states that
63% of PCa cases diagnosed in the US occurred in patients 65 years or over (Mordukhovish
et. al., 2010)
Tumor cells, whether they originate from prostate tissue or another neoplastic source,
develop as a result of certain genetic alterations (mutations) in key genes or transcription
factors involved in regulatory pathways controlling cell growth, proliferation, and function.
With each round of a cell’s replicative lifespan, dividing cells accumulate or are at risk of
accumulating gain-of-function or loss-of-function mutations which can damage or alter the
cell cycle in such a way that promotes neoplastic transformation. Cancerous cells are

9	
  

unlikely to develop as a result of any one mutation. Even mutations in proto-oncogenes
(gene whose mutation or increased expression has a high potential to cause cancer) often
require some corroborating mutation, infection, or environmental factor to express its full
neoplastic potential. However, with increasing age, the cells undergo countless rounds of
replication, each of which has the potential for mutations and transcriptional errors to occur.
Increasing age ensures, that given enough time, the ‘lethal’ combination of aberrant cells or
a key mutation in a proto-oncogene will cause a neoplastic transformation.
There is also a well-established hierarchy of risk for prostate cancer seen among the
different ethnicity groups (see figure 1). In the US, the observed incidence of prostate
cancer is markedly lower in Asian/Pacific Islanders and Native Americans/Alaska Natives at
approximately 83 cases per 100,000 as compared to Caucasians males at 146.3 cases per
100,000 (Jemal, 2010). The PCa incidence among Hispanic/Latino Americans (131.4 cases
per 100,000) is lower in comparison to Caucasian males but higher in the hierarchy than
Asian/Pacific Islanders and Native Americans/Alaska Natives (Jemal et al., 2010).
Meanwhile, African-American men have the highest incidence of PCa at 231.9 cases per
100,000 (Jemal et al., 2010). A similar risk hierarchy is observed in PCa death rates among
the different racial/ethnic groups (see figure 2).
Ironically, racial and ethnic minorities are under-represented among clinical trials
participant populations, particularly African-Americans and Hispanics/Latinos (Pinsky et al.,
2008). Few comparisons have been compiled in which the data includes the
Hispanic/Latino, Asian/Pacific Islander, or American Indian/Alaska Native groups in
numbers significant enough to generalize. Because of this accrual/enrollment disparity, the
discussion below will focus mainly on the Caucasian--African-American dichotomy.
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Overall, African-Americans are approximately 1.4 times more likely to develop PCa
than Caucasian men, the next highest ethnic group (Chornokur et al., 2010). SEER (the
Surveillance, Epidemiology, and End Results Program) found similar racial disparities in
PCa incidence rates for African-American and Caucasian males (Mordukhovich et al.,
2010). Not surprisingly these disparities are carried over into the prognosis, treatment and

Figure 1: Age-adjusted prostate cancer incidence rates per 100,000 population, stratified by
race/ethnicity, United States, 2002 – 2006.

.

Figure 2: Age-adjusted prostate cancer mortality rates per 100,000 population, stratified by
race/ethnicity, United States, 2002 – 2006
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PCa specific mortality rates. A greater percentage of African-American males are diagnosed
at later stages as compared to Caucasians males; Six percent of African-Americans have
distant metastasis at initial diagnosis vs. only 4% of Caucasians (Mordukhovich et al.,
2010). CDC (Centers for Disease Control and Prevention) indicates that African-American
males have an earlier onset of disease, on average being diagnosed with PCa 3 years earlier
than Caucasian males (Chornokur et al., 2010). Furthermore, a cohort study performed on
37 African-American PCa patients and 35 demographically matched Caucasian patients,
each receiving radical prostatectomy, showed that the percentage of African-American
males whose Gleason score was pathologically up-staged post-surgery was nearly double
that of Caucasian patients (49% vs. 26% respectively) (Chornokur et al., 2010). The study
also observed that African-American patients tended to have greater tumor volume, and 2.8
times more tumor per ng/ml of serum PSA than their Caucasian counterparts (Chornokur et
al., 2010).
The basis for these disparities is largely unknown, however, several viable
hypotheses have been purposed and explored by researchers. Some suggest that the
disparity between African Americans and Caucasians is due to lapses in the patterns and
quality of care (Barocas, et al., 2010). In studies looking at racial disparities in PCa and the
possible causes, it is observed that African-Americans are less likely to received radial
prostatectomy (a definitive, curative therapy) and more likely to receive radiotherapy or
watchful waiting (a delay of active treatment until such time as tumor progression is
detected) (Chornokur et al., 2010). These treatment decisions are possibly due to different
values and concerns among African-American men regarding the effects of invasive therapy
such as urinary dysfunction and long-lasting sexual impairment. Some studies suggest that
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the reason for these patterns, particularly those observed in African-Americans vs.
Caucasians are more a reflection of socio-economic disparities such as income, education,
health insurance and employment status (Barocas et al., 2010). There are a larger
percentage of African-American men that are unemployed (15.5% vs. 8.8% of Caucasians),
below the poverty line (24% vs. 8.6% of Caucasians), and without health insurance (19.5%
vs 10.4% of Caucasians) (Barocas et al., 2010).
A second theory points instead to hereditary pre-disposition or ethnicity-specific
biologic differences to explain racial disparities (Chornokur et al., 2010). GWAS studies,
which have been undertaken to search for causal or risk-baring genomic locations which
confer a hereditary pre-disposition to PCa development, have shown that certain SNPs
(single nucleotide polymorphisms) associated with PCa risk vary by race (Liu et al., 2011).
(Of note: of the 71 subgroups examined in the study, only 2 were of Asian descent and 4 of
African American descent.) (Liu et al., 2011). Results showed that some risk SNPs are only
significantly associated with PCa in European populations, likewise others are only
significant among Asians populations or African-American populations (Liu et al., 2011).
This suggests that the racial hierarchy observed in PCa incidence, prognosis and survival has
a basis in genetics and other biologic factors. It could be that certain; as yet unidentified,
ethnicity-specific biologic factor(s) are what drive some tumors to develop more
aggressively than others. Conversely, it has also been observed that PCa incidence rates in
Japanese men who immigrated to the United States were noticeably elevated in comparison
to Japanese men still residing in their native country (Crawford, 2009). This would seem to
suggest an environmental risk factor were at heart of racial disparities seen in PCa. There is
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also the possibility that several interlocking social, economic, and/or biologic factors would
best explain the racial hierarchy as opposed to a singular cause.
In addition to age and race, having a positive family history of PCa is a consistently
observed risk factor for PCa development. Case control studies done on African-American
populations in Jamaica and Caucasian populations in Canada both reveal significant results
among first-degree relatives. In the Jamaican study, pedigrees and family history
information were obtained from histologically proven cases and their demographically
similar controls (Glover et al., 1998). Individuals with a first degree relative with a history
of PCa were twice as likely to develop prostate cancer as individuals without a positive
family history (Glover et al., 1998). Among 263 cases, 30 patients had a father, son or
brother who also had PCa compared to only 15 of 263 controls (Glover et al., 1998). A
threefold difference was observed when examining more distant relatives. Nine cases had a
grandfather, grandson or uncle with PCa compared with only 3 controls with an affected
second-degree relative (Glover et al., 1998). In the Canadian study there were 640 PCa
cases and 639 demographically similar controls (Ghadirian et al., 1997). Fifteen percent
(94) of cases self-reported one or more relatives (father or brother or both) with a history of
PCa while only 5% (32) of controls revealed first degree relatives with a history of PCa
(Ghadirian et al., 1997). Again, a threefold difference is observed, suggesting that PCa does
indeed ‘run in the family’.
A U.S. study evaluated a cohort of 15,924 veteran twin pairs (31,848 individuals);
one thousand nine cases of PCa were identified within the cohort (Page et al., 1997).
Researchers found that 15.7% of monozygotic twins (MZ) showed pairwise concordance (of
PCa) in comparison to only 3.7% of dizygotic twins (DZ) (Page et al., 1997). Probandwise
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comparison revealed a 27.1% concordance rate for PCa in MZ twins over the 7.1% seen in
DZ twins (Page et al., 1997). This means a MZ twin whose brother was diagnosed with PCa
would have a fourfold higher likelihood of having PCa than a DZ twin whose brother had
been diagnosed with PCa (Page et al., 1997). Not surprisingly, the heritability (the
component of the total variation that is due to genetic factors) of PCa was approximately
57% (Page et al., 1997). Environmental factors are thought to account for the remaining
43%.
These and other studies done on the etiology and genetic epidemiology of PCa have
led scientists to classify prostate cancer into three distinctive types: sporadic, familial, and
hereditary PCa (Sacco et al., 2005). Sporadic PCa is defined as occurring randomly within
any given population, while familial PCa is defined as the observation of unpredictable
clustering of PCa among relatives. Hereditary PCa is defined generally as having an earlier
onset (an average of 6-7 years earlier) and very strong clustering pattern in families (Sacco
et al., 2005). The evidence remains conflicting as to what specific pattern of inheritance is
responsible for hereditary PCa. However, studies have consistently shown that family
history is an important risk factor in both familial and hereditary PC. Further research is
needed to identify and/or clarify the exact hereditary mechanisms and components that are
integral to predicting the risk, inheritance and development of PCa.

Significance and Specific Aims
Despite the significant impact of prostate cancer on the population at large, very little
research have been dedicated to identifying factors influencing participation in prostate
cancer-specific clinical trials critical to the development and implementation of new and/or
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improved diagnostic and therapeutic interventions. Also, unfortunately, clinical oncology
trials aimed towards developing new interventions have been hampered by historically low
accrual rates. Poor accrual and retention threaten the validity of and power supporting the
study outcomes. Studies looking at clinical trials accrual patterns in oncology consistently
show that clinical trial enrollment for adult cancer patients is dismally low at just 2 – 4% of
all diagnosed patients (Movsas et al., 2007; Mills et al., 2006; Lara et al., 2001). However,
much of the literature reporting accrual statistics on clinical trials participation is not specific
to prostate cancer. The majority is either generalized to include multiple neoplastic sites or
narrowed to investigate the accrual patterns and difficulties of an individual study or a
limited demographic cohort.
Gross et al (2005) looks at the effects of sociodemographics, the protocol factors and
the recruitment center have on enrollment of older patients onto (breast, lung, colorectal and
prostate) oncology protocols. Pinsky et al (2008) conducts a similar study, looking at the
enrollment of racial and ethnic minorities in a prostate, lung, colorectal, and ovarian cancer
screening trial. Hoyo et al (2003) focused specifically on barriers and strategies for
improving enrollment on to prostate cancer protocols, however, the cohort is restricted to
African-Americans.
On the broad end of the spectrum, Movsas et al (2007) examines clinical trial
enrollment patterns in oncology trials as a whole. Steinhauser et al. (2006) takes it a step
further and reports on the difficulties of recruiting and retaining patient participation on
longitudinal research aimed toward a large-body of serious illnesses including: late-stage
cancers, advanced congestive heart failure, and advanced chronic obstructive pulmonary
disease. Craig et al. (2010) and multiple studies conducted by Gross et al (2004, 2005)
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examine the effect of managed healthcare and new reimbursement policies on all clinical
oncology trial enrollment.
Other studies take a narrow approach. Many look at the successes and difficulties of
recruitment and accrual on specific, individual oncology trials. For example, Wallace et al.
(2006) reports on the accrual outcomes of a surgical prostatectomy vs. radiation
intervention, while, Heiney et al (2010) details the successful recruitment methods used to
accrue patients onto a PCa behavioral intervention trial. Only two studies were found to
focus specifically on factors influencing enrollment in prostate cancer clinical trials. A
Canadian survey study reported on the most influential factors that patients believe drive
their decision to participate in prostate cancer protocols (Davison et al., 2008). A second
family-oriented study analyzed the difficulties of enrollment and retention of PCa patients
and their significant others, but only on one specific prostate cancer longitudinal randomized
study (Northouse et al., 2006).
Because prostate cancer often has a more indolent course and thus a lower risk of
death especially among older men (>75 years of age) there may be unique factors driving
patient enrollment in prostate cancer clinical trials. The aim of this study is to evaluate
clinical trial enrollment in the Multidisciplinary Prostate Cancer Clinic at UT MD Anderson
Cancer Center and to assess if a clinical trial initiative, introduced in 2006, increased our
trial enrollment. The secondary aim is to evaluate what factors, if any, contributed to the
increased accrual. We hypothesize that increased clinical trial enrollment will be achieved
after the onset of a prostate cancer specific clinical trial enrollment initiative in the
Multidisciplinary Prostate Cancer Clinic at UT MD Anderson Cancer Center.
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Methods and Materials
Study Cohort
Between the years 2004-2008, 1,370 men with localized prostate cancer were seen in
the University of Texas MD Anderson Cancer Center Multidisciplinary Prostate Cancer
Clinic (MPCC) and subsequently received treatment at MD Anderson Cancer Center.
Prostate cancer patients seen in MPCC were self or physician referred, newly diagnosed
(within 6 months) with localized disease and had not received definitive treatment. Each
MPCC was composed of at least two physicians, an urologist and a radiation oncologist.
Patients specifically interested in trials also had the option of having a medical oncologist
present at the MPCC visit. In 2006, the clinical trial enrollment initiative was begun. The
enrollment initiative employed active recruitment of MPCC patients on to open protocols.
Information about specific protocols and their premise were posted in the clinic area. Based
on eligibility criteria and appropriateness, clinicians presented the various clinical trial
options to patients during the normal MPCC discussion of treatment options. Patients were
then handed a letter at the end of the visit that outlined treatment options that were discussed
with the patient, including a list of the trials that were offered to them.

Primary Outcome
The primary outcome was enrollment in a prostate cancer clinical trial. The
selection of prostate cancer clinical trials open to accrual was divided into four categories: a)
laboratory studies, b) quality of life (QOL) studies, c) procedure studies, d) novel studies.
Two physicians (KEH, DAK) and a nurse practitioner (LM) categorized the trials. All three
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agreed on the final characterization for all trials. The type of clinical trial and quantity of
clinical trials that each patient chose to participant in was recorded in the electronic medical
record.
Table 3: Four Categories of Clinical Trial Types
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Explanatory Variables
The explanatory variables evaluated for association with enrollment in a prostate
cancer clinical trial included: age, year of visit, self-reported race, residence and prostate
cancer risk group. Age was reported as a continuous variable, and then dichotomized on the
median age of the study population (younger = younger than 64.2 years, older = older than
64.2 years). In this way proportional enrollment was report based on age. Visit year was
evaluated as both a continuous and a categorical variable. Prostate cancer patients were
categorized as either having visited the MPCC before the clinical trial enrollment initiative
began in 2006 or after. Race was evaluated as a categorized variable: Caucasian, AfricanAmerican, or Other. Residence was categorized as either within the Houston ten-county
metropolitan statistical area or outside of the metropolitan area. The Houston-Sugar LandBaytown Metropolitan Statistical Area consists of Austin, Brazoria, Chambers, Fort Bend,
Galveston, Harris, Liberty, Montgomery, San Jacinto and Waller counties. Prostate cancer
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risk group was evaluated as a categorical variable: a) low-risk, stage T1a-T2a and Gleason
score ≤ 6 and PSA ≤ 10ng/ml; b) high-risk, stage T3-4 or Gleason score ≥ 8 or PSA > 20
ng/mL; c) intermediate-risk, all others.

Statistical Analysis
The SAS (v 9.2) statistical software was used to analyze the outcome data.
Descriptive statistics were generated to characterize the study cohort. Characteristics
included: visit year, age, ethnicity, risk group, patient residence, and clinical trial type.
Proportional clinical trial enrollment was reported (figure 3) as well as proportional increase
in trial enrollment (figure 6). In addition, total clinical trial enrollment was stratified by visit
year (figure 7), trial type (figure 4), and patient characteristics (figure 5) and by age (figure
8). The outcome variable was clinical trial enrollment. There were multiple explanatory
variables:






Year (as both continuous and dichotomized as 2004-2005 vs. 2006-2008)
Age
Ethnicity
Risk group
Residence
For univariate analysis, logistic regression analysis was used to evaluate the

association between clinical trial enrollment and each of the possible explanatory variables
on a one to one basis. Pearson’s chi square statistic was used to evaluate the significance of
characteristics of patients who enrolled on clinical trials, to report on clinical trial enrollment
by age group, to compare age vs. patient residence. Pearson’s chi square statistic was also
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used to evaluate the proportional enrollment increase broken down by trial type (see figure
6).
Multivariate logistic regression analysis was used to evaluate each variable’s
association with clinical trial enrollment while controlling for the influence of the other
covariates. To accomplish this, logistic regression modeling was used to evaluate which
characteristic(s) co-vary with trial enrollment. Logistic regression models were generated
using clinical trial enrollment as the outcome variable. Visit year was first run a continuous
variable, then rerun including visit year as a dichotomized variable (before and after the
implementation of a clinical trial initiative). For both univariate and multivariate logistic
regression analysis, the likelihood ratio chi-square was used to test for significance. The test
for significant difference was determined using a p-value. P-values less than .05 were
considered to represent a significant difference from zero…and thus a significant
association. Trends were defined in terms of p-value. P-values between 0.1 - .05 were
considered trends.
For both univariate and multivariate analysis odds ratio (OR) and adjusted Odds
ratios (AOR) with corresponding 95% confidence intervals were generated for each
covariate. The confidence interval is constructed at the 95% level in order to ensure the
reliability of the study data gathered from this investigation. If this study were repeated 100
hundred times and 100 confidence intervals were constructed, then we would expect 95 of
the hundred confidence intervals would contain the true, unknown, population parameters
that we are trying to estimate with this study.
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Results
Overview
A total of 1,370 prostate cancer patients were seen in the MD Anderson Cancer
Center MPCC between the years of 2004 and 2008 and subsequently received treatment at
MD Anderson Cancer Center. The median age at the time of visit was 64.2 years
(interquartile range = 57.6yrs – 69.5yrs). The vast majority of the men were Caucasian
(82.6%). African-American men represented 10.7% while other races made up the
remaining 6.7% of the study population. The study population consisted of 442 (32%) low
risk patients, 674 (49%) intermediate risk patients, and 254 (19%) high-risk patients.
Approximately 70% of men were permanent residents of the Houston Metropolitan area.
Thirty percent of the men resided outside the Houston Metropolitan area or outside the state
of Texas. Of the 1,370 patients, 326 (24%) men were seen in MPCC before the 2006
enrollment initiative began, and 1,044 (76%) were seen after the 2006 enrollment initiated
was implemented.
Of the total study population, 1,007 (73.5%) enrolled in at least one clinical trial,
while 390 (28.5%) enrolled in 2 or more clinical trials (figure 3). Sixty-seven percent
enrolled in laboratory studies, 18% enrolled in QOL studies, 3.7% enrolled in procedural
studies, and 13% enrolled in novel treatment studies. Total patient enrollment increased
from 38.9% before the clinical trial initiative to 84.3 % after the clinical trial initiative.
Patient enrollment increased from 25% to 80% in laboratory studies, from 9% to 21% in
procedural studies, from 6% to 15% in novel studies, and decreased from 8% to 2% in QOL
studies. Eighty-three percent of Caucasian patient were enrolled on clinical trials as
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compared to only 11% of African-American patients, and 6% of other race patients. Sixtysix percent of patients who resided in Houston Metropolitan were enrolled on clinical trials,
while only 34% of non-Houston residences were enrolled on clinical trials. Forty-nine
percent of patients of intermediate risk patients were enrolled on clinical trials, 32% of low
risk patients and 19% of high risk patients were enrolled on clinical trials. Seventy-nine
percent of younger age patients (younger than 64.2 years) were enrolled on clinical trials vs.
68% of older age patients (older than 64.2 years). Sixty-five percent of patients residing in
Houston were younger patients, 35% of non-Houston residents were younger patients.
Seventy-four percent of Houston residence patients were older patients while 26% of nonHouston residents were older patients.

Table 4: Characteristics of 1,370 men evaluated in a multidisciplinary prostate cancer clinic

Study Population
Total
Age (continuous)
Race/Ethnicity
Caucasian
African-American
Other

n

Median

1,370
64.2

n

%

1,132
146
92

82.6
10.7
6.7

442
674
254

32.3
49.2
18.5

951
419

69.4
30.6

326
1,044

23.8
76.2

Risk Group
Low risk
Intermediate risk
High risk

Residence
Within Houston Metro
Outside Houston Metro

Visit Year
Before Initiative 2004-2005
After Initiative 2006-2008
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None

26.5%

At least 1

73.5%
28.5%

2 or more
0.0%

25.0%

50.0%

75.0%

Figure 3: Total overall patient enrollment by number of trials
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Figure 4: Total patient enrollment by trial type.
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Figure 5: Characteristics of patients enrolled in clinical trials.
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Univariate analysis of factors associated with enrolling in a clinical trial
The year of MPCC visit was evaluated as both a continuous and a dichotomized
variable. When visit year was evaluated as a continuous variable, patients seen in later years
were more likely to enroll in a clinical trial (OR 2.33, 95% CI 2.09 – 2.63, p < 0.0001 per
year increase). Similarly, when year of visit was evaluated as a dichotomized variable,
patients seen after the 2006 enrollment initiative were more likely to enroll in clinical trials
that patient seen prior to the clinical trials initiative (OR 8.41, 95% CI 6.37 – 11.10 p <
0.0001). The overall proportion of patients enrolling in clinical trials increased from 38.9%
before the enrollment initiative to 84.3% after (

vs.

participants, respectively).

Residence and patient age at time of MPCC visit were also found to be associated with
clinical trial enrollment. Older men (OR 0.97, 95% CI 0.95 – 0.98, p < 0.0001 per year
increase) and men living outside the Houston Metropolitan area (OR 0.54, 95% CI 0.40 –
0.71, p <.0001) were less likely to participate in clinical trials than their younger age, locally
residing counterparts. Race and risk group were not shown to be associated with clinical
trial enrollment.
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Table 5: Factors associated with clinical trial enrollment on univariate analysis

Age
Continuous
Visit Year
Per year increase
Categorical year
Pre-initiative
Post-initiative

Odds Ratio (95% CI)

p-Value

0.97 (0.95, 0.98)

<.0001

2.35 (2.09, 2.63)

<.0001

Reference group

Reference group

8.41 (6.37, 11.10)

<.0001

Race/Ethnicity
Caucasian
African-American
Other

Reference group

Reference group

1.12 (0.75, 1.68)
0.66 (0.424, 1.04)

0.572
0.074

Residence
Houston metro area
Non-Houston metro area

Reference group

Reference group

0.54 (0.40, 0.71)

<.0001

Reference group

Reference group

0.98 (0.75, 1.29)
1.05 (0.74, 1.49)

0.887
0.799

Risk Group
Low
Intermediate
High

Multivariate analysis of factors associated with enrolling in a clinical trial
On multivariate analysis that adjusted for age, race, residence and prostate cancer
risk group, patients seen in the MPCC clinic in later years were more likely to enroll in
clinical trials (AOR 2.33, 95% CI 2.07 – 2.62, p < 0.0001 per year increase.) The year of
the patient’s clinic visit was analyzed as a dichotomized variable, before 2006 (before
enrollment initiative) and after 2006 (after enrollment initiative). Men seen in clinic after
implementation of the clinical trials enrollment initiative were more likely to enroll in a
clinical trial than men seen before implementation of the trial enrollment initiative (AOR
8.22, 95% CI 6.16 – 10.96, p < 0.0001). Patient age at the time of MPCC was also found to
be independently associated with clinical trial enrollment. Older patients were less likely to

28	
  

enroll in clinical trials than their younger counterparts (AOR 0.97, 95% CI 0.95 – 0.98, p <
0.0001 per year increase). Multivariate analysis indentified a trend for patients in the
highest prostate cancer risk group to be more likely to participate in clinical trials (AOR
1.43, 95% CI 0.96 – 2.13, p = 0.083) than low-risk patients. Multivariate analysis also
revealed that patients of ‘other’ races (namely, Hispanics, Asians, Indians and Native
Americans) were less likely to participate in clinical trials than Caucasians patients (AOR
0.56, 95% CI 0.34 – 0.94, p = 0.027).
Looking at visit year as continuous variable saw similar results except for
race/ethnicity. Although a trend was identified as for patients of ‘other’ races to be less
likely to participate in clinical trials than Caucasians patients (AOR 0.60, 95% CI 0.36, p =
0.054) it was not a statistically significant finding.

Table 6: Factors associated with clinical trial enrollment on multivariate analysis

Visit Year (Dichotomized)
Age
Visit Year
Race/Ethnicity
Caucasian
African-American
Other

Odds Ratio (95% CI)
0.97 (0.95, 0.98)
8.22 (6.16, 10.96)

p-Value
<.0001
<.0001

Reference group

Reference group

0.94 (0.59, 1.48)
0.56 (0.34, 0.94)

0.779
0.027

Residence
Houston metro area
Non-Houston metro area

Reference group

Reference group

0.80 (0.58, 1.10)

0.176

Reference group

Reference group

1.16 (0.85, 1.58)
1.43 (0.96, 2.13)

0.346
0.083

Risk Group
Low
Intermediate
High
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Discussion
Primary Finding
Our primary finding was that newly-diagnosed prostate cancer patients seen in the
MPCC after the onset of the 2006 clinical trial enrollment initiative were more likely to
enroll in prostate cancer clinical trials. This result is important because of the possible
implications it may have on enrollment patterns of patients onto prostate cancer clinical
trials. Identifying factors influencing participation in prostate cancer-specific clinical trials
is critical to the development and implementation of new strategies for bolstering enrollment
onto procedural and novel treatment investigations aimed toward improved diagnostic and
therapeutic interventions for prostate cancer.
Wallace et al. (2006) looked at the accrual outcomes of a single phase III randomized
trial comparing surgical prostatectomy vs. radiation intervention (SPIRIT) after the
development and implementation of a multidisciplinary education session. Similar to our
study, an enrollment initiative was developed both to education patients more thoroughly on
their treatment options and to facilitate increased study accrual. Their enrollment initiative
included an informative video about clinical trial participation following by a consultation
with both an urologist and a radiology that explained the rationale of the study. Before the
development of the multidisciplinary education session, 0 of 27 eligible patients who were
presented with the option of participating in the SPIRIT trial consented to enroll. After
implementation of the multidisciplinary education session, 47 sessions presented to 263
eligible patients yielded 34 participants. It has been showed with the SPIRIT study and this
study as well that enhanced patient understanding of available clinical trials, treatment
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options and the rationale for each, increases accrual. Active recruitment techniques such as
patient education, multidisciplinary counseling, and study advertisement tailored specifically
to enhance accrual of clinical trials in prostate cancer is important to the future of prostate
cancer research. These enrollment initiatives can only be developed effectively with
specific knowledge of what factors influence trial participation.
Secondary Finding
Our secondary finding suggests that age plays an important role in clinical trial
enrollment patterns of prostate cancer patients. It was revealed that older patients were less
likely to enroll in clinical trials than their younger counterparts. There are several probable
explanations for this finding. Possibly, younger patients are generally healthier than older
patients with more co-morbidities. Older patients are less able to meet the often-restrictive
eligibility criteria defined by some clinical trials. Physicians may, consciously or
unconsciously, adopt a more aggressive course of treatment with younger patients.
A similar study conducted by Trimble et al (1994) looked at not just prostate cancer
but also lung, colorectal, pancreatic and hematological cancers. Trimble found that the 65+
male population were underrepresented in cancer treatment trials. Of the total number of
male cancer patients enrolled in NCI sponsored clinical cooperative group treatment trials in
1992, only 39% were over 65 years of age. Since then, not much progress has been made in
accrual rates in older cancer patients. Fifteen years later, in 2007, Stewart et al. examined
gender, race/ethnicity, and age-based disparities in enrollment patterns specifically for
surgical oncology trials in breast, lung, colorectal, and prostate cancer patients collectively.
The study found that cancer patients 65-74 years old were less likely to be enrolled than
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those 20-44 years old, making the point that the lack of proper representation of older
patients in clinical trials is not restricted to prostate cancer alone. It is a widespread
problem, but it is particularly troublesome in PCa because 63% of the cases diagnosed in the
US occur in patients 65 years or over (Mordukhovish et. al., 2010). Thus, it is of great
importance that the segment of the population most commonly affected by prostate cancer
are adequately represented in clinical research aimed toward increasing the knowledge base
and developing new/improved diagnostic and treatment methods.

Tertiary Finding
Upon univariate analysis, it appeared as though patient residence was a contributing
factor in clinical trial enrollment, however upon multivariate analysis this association
dissipated. In univariate analysis, each patient characteristic was evaluated independently
for association with clinical trial enrollment. However, this is not ideal since realistically,
these characteristics can never truly exist separately. They exist collectively and often
interact with each other. Each patient is a certain age, a certain race, and lives in a certain
area, etc. All these things may play a roll in the patient’s decision to either enroll in or not
to enroll in a clinical trial. Often time correlation among co-variates can mask significance
in multivariate analysis. This could explain why it appeared that non-Houston residents
were less likely to enroll in clinical trails on univariate analysis. Upon multivariate analysis,
this association was not seen to be significant. It might be that non-Houston residence
younger age patients more willing to travel father for treatment. When patient residence was
crossed with patient age group it was noted that 35% of the non-Houston residents who
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enrolled in Clinical Trials were younger patient as compared to only 26% of the nonHouston residents were older patients. It should also be noted that part of the inclusion
criteria for this study requires that patients be seen and treated in the UT MD Anderson
Cancer Center’s MPCC regardless of whether they chose to be treated on-study or off-study.

Trends
Analysis of the dataset showed two additional findings that did not meet the criteria
for significance, nevertheless, they are worthy of note. There was a trend seen for high-risk
PCa patients to be more likely to enroll in clinical trials than the low risk patients. This
study also identified a trend for PCa patients of ‘Other’ races (namely, Hispanics, Asians,
Indians and Native Americans) to be less likely to participate in clinical trials than
Caucasian patients. There are several lines of reasoning which could explain these trends.
High-risk PCa patients were categorized as such because their PSA level, Gleason
score, and T-stage suggests that these patients had an increased risk of tumor recurrence
following treatment. A patient’s risk group status often guides the physician in making the
appropriate treatment recommendations. Clinical trials, because they are often testing
unproven therapies, are generally considered more aggressive than the proven standard-ofcare options. It might be that physicians recommend what they view as a more aggressive
treatment option to high-risk PCa patients more often than to low risk patients because high
risk patient are expected to have a worse prognosis. In turn, a high-risk patient might be
more willing to be treated on a PCa clinical trial because they perceive it as a more
aggressive approach to eradicating their cancer.
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In the US, the observed incidence of prostate cancer is lower in all the other races
(Hispanic, Native Americans, Asians and Indians) as compared to Caucasians (Jemal, 2010).
PCa incidence is lower among Hispanic races and lower still in Native and Asian Americans
Caucasians and African Americans, thus the pool of potential patients is smaller. Asian
Americans and Native Americans have the lowest incidence of PCa among the ethnic
groups. A smaller population base of PCa patients means fewer trial candidates and
therefore fewer clinical trials enrollees. There has also been research suggesting that
different social values and concerns (such as fear of loss of virility and sexual function, fears
of exploitation, and the spiritual/religious implications of treatment) among certain ethnic
groups compel some to delayed diagnosis and treatment, or opt to forgo diagnosis/treatment
altogether which could contribute to their underrepresentation in clinical trials. Socioeconomic disparities among different ethnic groups could also explain the lower
participation of ‘other’ race PCa patients in clinical trials. Lack of income, education and
adequate health insurance likely contributes to the lack of access to the full range of therapy
options, including, unfortunately clinical trial enrollment (particularly trials that require
costly out-of-pocket expenditures).

Strengths and Limitations
The results of our study, while viable, lack a certain degree of generalizability. This
is in part because data collection was confined to one site, the UT MD Anderson Cancer
Center MPCC. There is also an unbalanced racial/ethical distribution among the study
cohort. The vast majority of the participants were Caucasian males. As is true of clinical
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trials in general, minorities are not adequately represented. This is particularly concerning
to our study, considering African-American minorities have a disproportionately increased
risk and incidence of prostate cancer and yet they remain underrepresented in prostate
cancer clinical trials research. Future studies looking at accrual patterns in PCa patients
should seek to include multiple study sites in order to broaden the variety of patients and to
possibly recruit a higher percentage of minorities. Specific strategies should be
implemented to target increasing clinical trial enrollment among African-Americans and
other minority patients. This research is needed because some factors associated with
clinical trials enrollment may vary with ethnicity. In addition, socioeconomic factors, which
could possibly play an important roll in clinical trial enrollment particularly in minority
populations, were not explored in this study.
The way in which the study was designed captures the trial type and number of
clinical trials each patient chose to participate in, but not the total number and type of trials
each patient was initially offered. Additionally, the trial design included a large
heterogeneity of clinical trials, (laboratory studies, QOL, procedural and novel studies). It
might be interesting and possibly more informative to examine one specific trial type.
Another consideration not taken into account by the experimental design is the continuity of
trial offerings over time. It could be that more trials were available after the enrollment
initiative began. If there were less trial offerings available for patients seen before the
initiative began, then there was a slight handicap to trial enrollment inherent to the
experimental design, which was not controlled for. This begs the question, did trial
enrollment increased because of the enrollment initiative or because of increased trial
availability after the initiative.
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Another similar issue is the number of each trial type available over time. Were the
pool of potential clinical trials saturated with a majority of one trial type (ex. lab studies) at
certain points of time, while other trial types were in short supply (QOL)? The fact that
QOL studies were the only trial type that decreased rather than increased in enrollment after
the enrollment initiative could be explained by a lack of availability of QOL trials in those
years rather than a conscience decision by patients against the trial type. Uncontrolled
variables in the study design such as trail availability and trial continuity over time tend to
weaken the confidence is the study’s outcome.
The major strength of the study was that it captured prostate cancer patients seen in
the MPCC over a span of several years. A second strength of the study is that by having all
data collected at one site there is better completeness and continuity of data. Examining an
enrollment initiative impact on clinical trial accrual patterns at pre and post time points and
then running a statistical analysis of the study data is a very straightforward study design.
The outcome and conclusions that are drawn from the data are likewise unambiguous and
can be readily incorporated into future investigations.

Recommendations
In future studies, there is a need to include multiple study sites in the collection of
data. A conscious effort should be made to target minority enrollment in clinical trials,
perhaps even focus entirely on minority recruitment with a newly designed enrollment
initiative directed specifically toward under-represented ethnic populations. Making these
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two adjustment to future trials would help to increase the generalizeability of the study
outcome(s).
Additional alterations should be made in the study design in order to control for
clinical trial availability and trial type availability over time. It would strengthen the study’s
internal validity if the quantity of trails available were held constant throughout the study.
Likewise, an equal quantity of each trial type should be available throughout the study so
that any increase or decrease in trial enrollment observed could be more confidently
attributed to the enrollment initiative and not muddied by uncontrolled competing variables.
It might be a worthwhile endeavor to take a more microscopic approach to the
subject matter. It would be interesting to focus on one specific trial type or even one
individual trial and design an enrollment initiative tailored to enhance accrual on to just that
trial type or that one clinical trial. This design might be more time-consuming. A pilot
period may be required, wherein the study is run specifically to gauge patient interest in
and/or initial reaction to participation in the study. Based on patient reactions and /or
recommendations (captured via a survey or questionnaire) a suitable enrollment initiative
could then be tailored to meet the needs of the individual trial or trial type.

Conclusion
Clinical trial enrollment in our multidisciplinary clinic was substantially higher than
seen nationally in adult cancer patients. Enrollment rates increased after introduction of a
clinical trial initiative. We further conclude that age plays an important role in clinical trial
enrollment patterns of prostate cancer patients. We speculate we achieved high enrollment
37	
  

rates because 1) specific trials are discussed at time of treatment recommendations, 2) we
provide a letter documenting offered trials and 3) we introduce patients to the research team
at the same clinic visit if they are interested in trial participation.
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